Anti-Tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer

Exclusion Criteria

• •Resectable pancreatic adenocarcinoma as discussed by our multidisciplinary hepatobiliary team;
• •Successful down staging after (radio)chemotherapy from previous unresectable/borderline tumor to resectable tumor;
• •History of epilepsy;
• •History of cardiac disease:
• •* Congestive heart failure \>NYHA class 2;
• •* Active Coronary Artery Disease (defined as myocardial infarction within 6 months prior to screening);
• •* Cardiac arrhythmias requiring anti-arrhythmic therapy or pacemaker (beta blockers for antihypertensive regimen are permitted);
• •Uncontrolled hypertension. Blood pressure must be ≤160/95 mmHg at the time of screening on a stable antihypertensive regimen;
• •Compromised liver function (e.g. signs of portal hypertension, INR \> 1,5 without use of anticoagulants, ascites);
• •Uncontrolled infections (\> grade 2 NCI-CTC version 3.0);
• •Pregnant. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment;
• •Immunotherapy ≤ 6 weeks prior to the procedure;
• •Chemotherapy ≤ 6 weeks prior to the procedure;
• •Radiotherapy ≤ 6 weeks prior to the procedure;
• •Concomitant use of anti-convulsive and anti-arrhythmic drugs (other than beta blockers used for antihypertensive);
• •Allergy to contrast media;
• •Any implanted stimulation device;
• •Any implanted metal stent/device within the area of ablation that cannot be removed;
• •Any condition that is unstable or that could jeopardize the safety of the subject and their compliance in the study; Of note, patients with contra-indications for MRI will not be excluded from participation: in this case radiologic follow-up will consist of CT-scanning according to protocol.